Self-tolerance does not restrict the CD4+ T-helper response against the p53 tumor antigen

Cancer Research

Volumn 68, Issue 3, 2008, Pages 893-900

  Lauwen, Marjolein M ^a   Zwaveling, Sander ^a   De Quartel, Linda ^a   Ferreira Mota, S Carmela ^a   Grashorn, Janine A C ^a   Melief, Cornelis J M ^a   Van Der Burg, Sjoerd H ^a   Offringa, Rienk ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; PROTEIN P53; SYNTHETIC PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; DRUG DOSE ESCALATION; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MAGNITUDE ESTIMATION METHOD; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODY AFFINITY; ANTIGEN PRESENTATION; CANCER VACCINES; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; FEMALE; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; SELF TOLERANCE; T-LYMPHOCYTES, HELPER-INDUCER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 38849183472     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-3166     Document Type: Article

References (33)

1. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53.
2. Rogel A, Popliker M, Webb CG, Oren M. p53 cellular tumor antigen: analysis of mRNA levels in normal adult tissues, embryos, and tumors. Mol Cell Biol 1985;5:2851-5.
3. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997;185:833-41.
4. Hernandez J, Lee PP, Davis MM, Sherman LA. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire. J Immunol 2000;164:596-602.
5. Hernandez J, Ko A, Sherman LA. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J Immunol 2001;166:3908-14.
6. Fedoseyeva EV, Boisgerault F, Anosova NG, et al. CD4+ T cell responses to self- and mutated p53 determinants during tumorigenesis in mice. J Immunol 2000;164:5641-51.
7. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000;60:1777-88.
8. van der Burg SH, de Cock K, Menon AG, et al. Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur J Immunol 2001;31:146-55.
9. van der Burg SH, Menon AG, Redeker A, et al. Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors. Int J Cancer 2003;107:425-33.
10. Zwaveling S, Vierboom MP, Ferreira SC, et al. Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 2002;62:6187-93.
11. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 1991;49:281-355.
12. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.
13. Melief CJ, van der Burg SH, Toes RE, Ossendorp F, Offringa R. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol Rev 2002;188:177-82.
14. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 1995;3:407-15.
15. Sandberg JK, Franksson L, Sundback J, et al. T cell tolerance based on avidity thresholds rather than complete deletion allows maintenance of maximal repertoire diversity. J Immunol 2000;165:25-33.
16. Cordaro TA, de Visser KE, Tirion FH, Schumacher TN, Kruisbeek AM. Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection? J Immunol 2002;168:651-60.
17. Slifka MK, Blattman JN, Sourdive DJ, et al. Preferential escape of subdominant CD8+ T cells during negative selection results in an altered antiviral T cell hierarchy. J Immunol 2003;170:1231-9.
18. Bos R, van DS, van HT, et al. Expression of a natural tumor antigen by thymic epithelial cells impairs the tumor-protective CD4+ T-cell repertoire. Cancer Res 2005;65:6443-9.
19. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992;356:215-21.
20. Franken KL, Hiemstra HS, van Meijgaarden KE, et al. Purification of his-tagged proteins by immobilized chelate affinity chromatography: the benefits from the use of organic solvent. Protein Expr Purif 2000;18:95-9.
21. Khan S, Bijker MS, Weterings JJ, et al. Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells. J Biol Chem 2007;282:21145-59.
22. Hurpin C, Rotarioa C, Bisceglia H, Chevalier M, Tartaglia J, Erdile L. The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. Vaccine 1998;16:208-15.
23. Rescigno M, Winzler C, Delia D, Mutini C, Lutz M, Ricciardi-Castagnoli P. Dendritic cell maturation is required for initiation of the immune response. J Leukoc Biol 1997;61:415-21.
24. Winzler C, Rovere P, Rescigno M, et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997;185:317-28.
25. van Hall T, van de Rhee NE, Schoenberger SP, et al. Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes. Cancer Res 1998;58:3087-93.
26. Vierboom MP, Nijman HW, Offringa R, et al. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997;186:695-704.
27. Vierboom MP, Zwaveling S, Bos GMJ, et al. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res 2000;60:5508-13.
28. Vierboom MP, Bos GM, Ooms M, Offringa R, Melief CJ. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int J Cancer 2000;87:253-60.
29. Zwaveling S, Ferreira Mota SC, Nouta J, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169:350-8.
30. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991;351:453-6.
31. Gallucci S, Lolkema M, Matzinger P. N atural adjuvants: endogenous activators of dendritic cells. Nat Med 1999;5:1249-55.
32. Offringa R, Vierboom MP, van der Burg SH, Erdile L, Melief CJ. p53: a potential target antigen for immunotherapy of cancer [discussion 233-6]. Ann NY Acad Sci 2000;910:223-33.
33. Chikamatsu K, Albers A, Stanson J, et al. P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res 2003;63:3675-81.